BACKGROUND: Hypererythropoietinemia is associated with common diseases like non-uremic anaemia where infection burden is high. Erythropoietin (EPO) is also given as therapy for anaemia associated with chronic kidney disease and cancer and in those who are at a higher risk of infections. EPO is known to have an effect on macrophages by which it helps in the growth of some intracellular pathogens. However, its direct role on bacterial growth is currently unknown. SUMMARY: Here, we investigated the direct effect of recombinant human erythropoietin (rhuEPO) on the growth of pathogenic Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. In silico experiments were designed to gain insight into the mechanisms. We found that 30 IU/L rhuEPO promoted the growth of E. coli and S. aureus and inhibited the growth of P. aeruginosa. In silico observations suggest that bacterial cell surface proteins may interact with the EPO and may cause the observed effects. KEY MESSAGE: It appears that some pathogens can explore EPO to proliferate and growth of others are inhibited by the same. The consequence of such observation is a matter of widespread concern for future research.
BACKGROUND: Hypererythropoietinemia is associated with common diseases like non-uremic anaemia where infection burden is high. Erythropoietin (EPO) is also given as therapy for anaemia associated with chronic kidney disease and cancer and in those who are at a higher risk of infections. EPO is known to have an effect on macrophages by which it helps in the growth of some intracellular pathogens. However, its direct role on bacterial growth is currently unknown. SUMMARY: Here, we investigated the direct effect of recombinant human erythropoietin (rhuEPO) on the growth of pathogenic Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa. In silico experiments were designed to gain insight into the mechanisms. We found that 30 IU/L rhuEPO promoted the growth of E. coli and S. aureus and inhibited the growth of P. aeruginosa. In silico observations suggest that bacterial cell surface proteins may interact with the EPO and may cause the observed effects. KEY MESSAGE: It appears that some pathogens can explore EPO to proliferate and growth of others are inhibited by the same. The consequence of such observation is a matter of widespread concern for future research.
Authors: Howard L Corwin; Andrew Gettinger; Ronald G Pearl; Mitchell P Fink; Mitchell M Levy; Marc J Shapiro; Michael J Corwin; Theodore Colton Journal: JAMA Date: 2002-12-11 Impact factor: 56.272
Authors: D M Musher; I Alexandraki; E A Graviss; N Yanbeiy; A Eid; L A Inderias; H M Phan; E Solomon Journal: Medicine (Baltimore) Date: 2000-07 Impact factor: 1.889
Authors: Tatjana Naranda; R Ilene Kaufman; Jin Li; Kenneth Wong; Annegret Boge; Dan Hallén; Kim Y C Fung; Mark W Duncan; Niels Andersen; Avram Goldstein; Lennart Olsson Journal: Endocrinology Date: 2002-06 Impact factor: 4.736
Authors: F Tamion; V Le Cam-Duchez; J F Menard; C Girault; A Coquerel; G Bonmarchand Journal: Anaesth Intensive Care Date: 2005-10 Impact factor: 1.669
Authors: V Pavlović-Kentera; G K Clemons; L Biljanović-Paunović; D Marisavljević; V Lezaić; M Pokrajac; L Djukanović Journal: Biomed Pharmacother Date: 1992 Impact factor: 6.529
Authors: Lindsey C Pingel; Karl G Kohlgraf; Christopher J Hansen; Christopher G Eastman; Deborah E Dietrich; Kindra K Burnell; Rupasree N Srikantha; Xiangjun Xiao; Myriam Bélanger; Ann Progulske-Fox; Joseph E Cavanaugh; Janet M Guthmiller; Georgia K Johnson; Sophie Joly; Zoya B Kurago; Deborah V Dawson; Kim A Brogden Journal: Immunol Cell Biol Date: 2008-08-19 Impact factor: 5.126
Authors: Tomas Ganz; George R Aronoff; Carlo A J M Gaillard; Lawrence T Goodnough; Iain C Macdougall; Gert Mayer; Graça Porto; Wolfgang C Winkelmayer; Jay B Wish Journal: Kidney Med Date: 2020-03-27